How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market
- By Interventional Procedure Type: Bronchoscopic Lung Volume Reduction (BLVR), Airway Stenting, Endobronchial Valve Placement, Bronchial Thermoplasty, Cryotherapy
- By Device Type: Endobronchial Valves, Bronchial Stents, Thermal Ablation Devices, Cryotherapy Probes, Balloon Catheters
- By Indication: Severe Emphysema, Chronic Bronchitis, Airway Obstruction, Refractory COPD Exacerbations, Bronchiectasis Associated with COPD
- By Patient Population: Severe COPD Patients, Moderate-to-Severe COPD Patients, Patients with Hyperinflation, Patients with Frequent Exacerbations, Non-surgical Candidates
- By Treatment Setting: Hospital-based Interventional Pulmonology Units, Outpatient Clinics, Specialized Respiratory Centers, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Bronchoscopic Lung Volume Reduction (BLVR) leads By Interventional Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Interventional Procedure Type 5
Device Type 5
Indication 5
Patient Population 5
Treatment Setting 4
Companies profiled
Boston Scientific Corporation
Medtronic plc
Olympus Corporation
Smith & Nephew plc
Cook Medical
Teleflex Incorporated
Stryker Corporation
Becton
Dickinson and Company
ConvaTec Group PLC
Bard Medical (BD)
Halyard Health (now part of Owens & Minor)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Olympus Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Smith & Nephew plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Teleflex Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dickinson and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →ConvaTec Group PLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bard Medical (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Halyard Health (now part of Owens & Minor)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →EndoChoice
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pulmonx Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Aerin Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,104M by 2033 · 6.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bronchoscopic Lung Volume Reduction (BLVR)41.2
- Airway Stenting17.3
- Endobronchial Valve Placement14.9
- Bronchial Thermoplasty8.9
- Cryotherapy17.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,240M → $2,171M · 7.3%
Europe$864.3M → $1,536M · 7.5%
Asia Pacific$789.1M → $1,310M · 6.5%
Latin America$488.5M → $719.9M · 5.0%
Middle East and Africa$375.8M → $573.8M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.212026
6.212027
6.222028
6.242029
6.252030
6.272031
6.282032
6.302033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation8.2
- Medtronic plc27.1
- Olympus Corporation10.7
- Smith & Nephew plc8.4
- Cook Medical9.4
- Teleflex Incorporated8.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Interventional Procedure Type29.1%
Device Type14.3%
Indication12.5%
Patient Population15.6%
Treatment Setting28.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe24.3
- Asia Pacific20.8
- Latin America11.4
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 82 | 92 | 94 | 77 | 76 | 84 | 84 |
| Medtronic plc | 89 | 68 | 73 | 78 | 72 | 91 | 79 |
| Olympus Corporation | 74 | 63 | 74 | 77 | 82 | 71 | 74 |
| Smith & Nephew plc | 71 | 75 | 64 | 74 | 80 | 69 | 72 |
| Cook Medical | 64 | 52 | 63 | 52 | 62 | 61 | 59 |
| Teleflex Incorporated | 62 | 66 | 56 | 67 | 53 | 62 | 61 |
| Stryker Corporation | 40 | 49 | 63 | 61 | 64 | 57 | 56 |
| Becton | 51 | 43 | 55 | 42 | 47 | 35 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- Medtronic plc
- Olympus Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Medtronic plc | ✓ | − | ✓ | ◐ | ✓ | ◐ |
| Olympus Corporation | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Smith & Nephew plc | − | ◐ | ◐ | − | ◐ | − |
| Cook Medical | ◐ | ◐ | − | ◐ | − | ◐ |
| Teleflex Incorporated | − | ◐ | ◐ | ◐ | ◐ | − |
| Stryker Corporation | − | − | ◐ | ◐ | − | ◐ |
| Becton | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation84
2Medtronic plc79
3Olympus Corporation74
4Smith & Nephew plc72
5Teleflex Incorporated61
6Cook Medical59
7Stryker Corporation56
8Becton46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boston Scientific CorporationMedtronic plc
Challenger2
Strong scale, closing on the leaders.
Olympus CorporationSmith & Nephew plc
Contender2
Focused players with pockets of strength.
Cook MedicalTeleflex Incorporated
Niche2
Specialists in a single segment or region.
Stryker CorporationBecton
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Interventional Procedure Type in North America, then scale across Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market — a $322M beachhead inside a $6.29B market.
Beachhead (SOM)$322Mobtainable near-term
Serviceable (SAM)$2.27Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Bronchoscopic Lung Volume Reduction (BLVR)
Best fit — highest urgency & budget in Interventional Procedure Type.
Economic buyer79 fit
Airway Stenting
Strong fit — clear ROI and a fast path to value.
End user68 fit
Endobronchial Valve Placement
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Interventional Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Device Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel28%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Interventional Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation13%
Closed-won7%
$15.9KCAC
$56KLTV
3.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market is a resilient opportunity — $4.90B by 2033, compounding at 4.7%.
TAM · 2025$3.39Btoday
TAM · 2033$4.90Bforecast
CAGR4.7%2027–2033
Cumulative$36.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.90BTotal addressable market
SAM$1.70BServiceable available market
SOM$334MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Interventional Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Interventional Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.90BLarge & growingTAM by 2033 at 4.7% CAGR
$1.70BServiceable nowreachable with today’s model
$334MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.82BBear3.1% CAGR
$4.90BBase4.7% CAGR
$6.28BBull6.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Device Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market — a $5.17B market by 2033. Plan: grow share from 10.9% to 18.3%.
Market size · 2033$5.17Btotal addressable
Market CAGR5.3%2027–2033
Target share18.3%from 10.9% today
Revenue ambition$946Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 18.3% | On track |
| Revenue | $570M | $946M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 28.4% | 43.6% | Behind |
| Customer retention | 91.3% | 96.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Interventional Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Device Type capability
A defensible second engine — invest in Device Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Interventional Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Device Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $124M capacity & capability investment
- Greenlight bolt-on M&A in Device Type
- Authorise North America expansion plan
- Fund R&D program for Interventional Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market conversation — a $3.02B market you can size, segment and defend in minutes.
Market size · 2033$3.02Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers1,209+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Interventional Procedure Type
Goal Grow share in Interventional Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Boston Scientific CorporationMedtronic plcOlympus CorporationSmith & Nephew plcCook MedicalTeleflex IncorporatedStryker CorporationBecton+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Interventional Oncology Devices Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportInterventional Oncology Ablation Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportInterventional Oncology Ablation Device Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportInterventional Neurological Devices Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportInterventional Medical Devices Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportInterventional Lung Solutions Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportInterventional Imaging Solutions Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportInterventional Image Guided System Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportInterventional Heart Valve Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportInterventional Fluoroscopy X-ray Machine Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportInterventional ENT Devices Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportInterventional Devices for Structural Heart Disease Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.